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Abstract
As for many other cancers, metastasis is the leading cause of death of patients with ovarian cancer. Vigorous
basic and clinical research is being performed to initiate more efficacious treatment strategies to improve the poor
outcome of women with this cancer. Current treatment for ovarian cancer includes advanced cyto-reductive surgery
and traditional platinum and taxane combined chemotherapy. Clinical trials using novel cytotoxic reagents and
tyrosine kinase inhibitors have also been progressing. In parallel, the application of robust unbiased high throughput
research platforms using transcriptomic and proteomic approaches has identified that not only individual cell
signalling pathways, but a network of molecular pathways, play an important role in the biology of ovarian cancer.
Furthermore, intensive genomic and epigenetic analyses have also revealed single nucleotide polymorphisms
associated with risk and/or aetiology of this cancer including patient response to treatment. Taken together, these
approaches, that are advancing our understanding, will have an impact on the generation of new therapeutic
approaches and strategies for improving the outcome and quality of life of patients with ovarian cancer in the near
future.
Keywords: Ovarian cancer; Metastasis; Chemoresistance; Targeted
therapy; Pharmacogenomics
Introduction
Malignant tumors have become a severe burden on the health
system of numerous countries, with treatment resistant metastasis, the
leading cause of death of patients including women with ovarian
cancer [1,2]. Ovarian cancer remains the leading cause of death from
all gynaecological tumors due to the lack of both symptoms at an early
stage and a reliable clinical test. The majority (85-90%) of ovarian
cancer is classified as epithelial histology and is the most aggressive
form of this cancer. The dismal fact is that 75% of patients are
diagnosed when the tumor has spread or metastasized into the
peritoneal wall or abdominal cavity. Clinically, it has been a challenge
to surgically remove all of the tumors even with advanced aggressive
cyto-reductive approaches, and therefore chemotherapy with cytotoxic
reagents is routinely administered following surgery. Most women
respond to the chemo-treatment initially but the tumor will become
resistant eventually leading to relapse; and this recurrent and chemo-
resistant disease is the main cause of patient deaths. Over the past
three decades, efforts have been made to overcome resistance to the
front line platinum-taxane regimen. For platinum-taxane refractory
cases, other options (as discussed below) are available such as,
Pegylated Liposomal Doxorubicin (PLD), gemcitabine, the
topoisomerase inhibitors, topotecan and etoposide, or a hormonal
regimen with combined tamoxifen and anastrozole to reduce estrogen
levels in the body [3]. However, the relapsed tumor cellular response
rate to each drug eventually decreases leading to patient death. The
development and clinical application of these drugs needs reliable
preclinical predictive models to determine their therapeutic efficacy in
advance. In addition, current cancer research has revealed that the
response of tumor cells to certain treatments varies in individuals as
their molecular phenotypes and tumor microenvironments differ
[4,5]. For this reason, numerous in vitro cell culture platforms have
been established and utilised in preclinical studies to better mimic the
tumor microenvironment seen in patients [6]. At present, cancer
derived cell lines are the major tool for research and preclinical testing
of the therapeutic potential of these new drugs. In this review, we wish
to summarise the current understanding, novel therapeutic agents and
approaches to ovarian cancer treatment, to lay a foundation for our
further research leading to new treatment for this disease.
Ovarian Cancer Pathogenesis
As for many other cancers, ovarian cancer is now recognised to
have a heterogeneous nature as we have achieved a better
understanding of the origin, development and progression of this
cancer over the past 10 years. Conventional pathology has divided
epithelial ovarian cancer into endometrioid, serous, clear cell and
mucinous subtypes according to its histological phenotypes with many
different immunohistochemical markers for the different subtypes
being described (Figure 1) [7]. Traditionally, epithelial ovarian cancer
is believed to derive from a single layer of flat or cuboidal mesothelial
cells covering the ovary. Recent pathological studies have shown that
ovarian cancer may arise from other organs, such as, high grade serous
cancer from the fallopian tube after seeding in the ovary [8-11].
However, the site of origin cannot be determined from the pathology
alone and increasingly is relying on molecular phenotypes to assist in
this regard. Recent studies on combined clinical, molecular and
genetic characteristics have proposed a two pathway model for this
cancer: Type I and Type II tumors [12]. Type I tumors display low-
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grade nuclear and architectural features, slow growth, and are
associated with well-defined benign and borderline (low malignant
potential) precursor lesions. Type II tumors comprise almost all of
high grade serous epithelial ovarian cancer, with a high growth rate,
metastasis and a less than 30% 5-year patient survival rate [13].
Furthermore, we now have a better understanding that due to the lack
of anatomical barrier around the ovary, ovarian cancer cells are shed
from the primary tumor site into the abdominal cavity as single cells
or clusters that are floating in the peritoneal fluid [14]. These
individual ovarian cancer cells and clusters adhere to the peritoneal
membrane, invading into the underlining extracellular matrices and
grow as secondary tumors. The metastasized tumors block lymphatic
drainage leading to accumulation of fluid in the abdominal cavity,
called ascites. In this scenario, patients have both solid tumors in the
stroma and ovarian cancer cells/clusters floating in the ascites fluid as
well. This clinical feature has been associated with poor outcome for
women with this cancer, in particular the aggressive high grade serous
histotype Type II tumors. While the underlining molecular
mechanisms involved in these processes are still a major focus of
ongoing research into metastatic spread, epigenetic association studies
also have been in progress.
Figure 1: Immunohistochemical staining representatively showing
the use of KLK7 as a biomarker for serous and endometriod
ovarian cancer. Little to no expression of KLK7 in the normal ovary
(A), moderate to strong intensity of KLK7 staining in endometrioid
(B), primary (C) and metastatic (D) serous ovarian cancer.
Genetics Aspect of Ovarian Cancer
To unravel the complex nature of ovarian cancer biology, numerous
studies have been carried out to search for genetic risk factors and to
characterize molecular phenotypes of this tumor. For example, women
carrying inherited mutations of BRCA1 and/or BRCA2 have increased
risk in developing ovarian as well as breast cancers [2]. In Type I
tumors, KRAS and BRAF mutations that activate the Mitogen-
Activated Protein Kinase (MAPK) signaling pathway are frequent
[15-17]. Mutation of the gene for Phosphoinositide 3-Kinase (PI3K)
inducing activation of the PI3K/AKT/mTORsignaling pathway has
also been reported in Type I tumors [15-17]. On the other hand,
mutations of TP53, CCNE1 and chromosome instability are found in
more than 80% of cases with Type II tumors [11,18]. In these tumors,
integrated genomic analyses have demonstrated different gene
signatures which have subdivided the high grade serous epithelial
ovarian cancers into differentiated, immunoreactive, mesenchymal
and proliferative sub-groups [19]. In addition, regulation of ovarian
cancer progression by microRNAs has revealed a cohort of potential
biomarkers for diagnosis and monitoring of this disease [20]. The
heterogeneous nature of ovarian cancer also makes it vital to identify
susceptible risk loci, which may be able to attribute its many different
sub-types to a reasonably distinct molecular basis, and also to establish
molecular signatures which can aid in its diagnosis and prognosis.
Single Nucleotide Polymorphisms (SNP) in Ovarian Cancer
Single Nucleotide Polymorphisms (SNPs) have been implicated in
instances of drug resistance during treatment, mostly due to the
expression and regulation variability they bring in individual genomes
[21]. This makes the knowledge derived from genetic association
studies valuable and clinically relevant for personalised medicine
initiatives in future ovarian cancer treatment. Until the last decade,
genetic association studies have been mainly undertaken using
candidate gene approaches, which are relatively cheap and quick to
perform and are focused on the selection of genes that have been
related to the disease previously and thus are based on previous
findings and require prior knowledge about gene function. Many
researchers have undertaken the candidate gene study approach and
identified risk alleles. An in depth analysis of recent ovarian cancer
research reviewed by Braem et al., attribute genetic pathways of DNA
repair, cell cycle, sex steroid hormone and oncogenic pathways of most
relevance in assessing risk susceptibility [22] when observed through a
priori gene studies. A few examples of candidate genes and
corresponding genetic variants most successful in ascertaining a
statistically significant association with ovarian cancer, in the order of
the affiliated pathways, are as follows.
A SNP, rs11226, in RAD52 has been reported to be a significant
ovarian cancer susceptible locus among DNA repair genes, as shown
by studies from Auranen et al. [23], Quaye et al. [24], and Beesley et al.
[25]. SNP rs2854344 in the RB1 gene, one of the cell cycle genes,
showed a high risk association in two studies conducted in 2006 [26]
and 2008 [27]. The validity of the Androgen Receptor (AR) gene as a
sex steroid hormone receptor involved in ovarian cancer susceptibility
has been shown in various studies (mentioned in [22]). SNP rs523349
in the SRD5A2 gene also been shown as a significant variant [25],
among other hormone regulating genes. Another involvement of
steroid hormones were seen by the up regulation of Kallikrein
(KLK)10 expression by estrogen and estrogen plus progesterone
treatment in aggressive ovarian cancers, followed by discovery of
functional KLK10 SNPs in that loci [28]. Among the kallikrein genes,
another instance of oncogenic involvement was noted in ovarian
cancer survival with the SNP (rs266851) disrupting KLK15 splice
variant [29]. Ratner et al., in an exploration study followed by a
validation study [30], formed links between a KRAS oncogene with a
variant allele harbouring SNP rs61764370 which disrupted the let-7
miRNA binding site on the gene. Another example of probable and
significant risk allele is in the FGF2 gene (rs308447), uncovered by
Johnatty et al. in 2009 [31] as a part of the Ovarian Cancer Association
Consortium (OCAC). A recent study carried out to link the VEGF
gene variants to ovarian cancer demonstrated the association of
rs833068 with poor survival rates in Australian woman [32].
Albeit that there are several advantages of candidate gene
association studies, they have also been criticised on various other
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accounts due to non-replication of the results. Considering these
aspects along with cumulative effect of multiple loci,and also complex
disease heterogeneity, a fine tuning of the candidate gene approach in
the future has been highly recommended [22,33]. The last decade has
specifically seen a success in identifying ovarian cancer loci using
Genome Wide Approaches (GWAS). This research has been driven by
technological advances including mainly chip based technology and
availability of robotics, that enabled very high throughput DNA
scanning approaches in very large cohorts through large
collaborations. GWAS included that conducted by the OCAC
consortium have identified 14 independent risk loci for ovarian cancer
imparting low- moderate risk. These loci are summarised in Table 1
derived from the NHGRI GWAS catalogue (http://www.genome.gov/
GWASStudySNPS.cfm?id=7213). Some of these loci are specifically
associated with sub-phenotypes of ovarian cancer. The clinical use of
these GWAS risk loci as early disease biomarkers is still not clear as
each one of them imparts only moderate effects. These SNPs in
combination along with high risk loci e.g. BRCA1/2 might have better
predictive values. These large efforts however have identified many
novel biological pathways and candidates for future targeted drug
therapies and are expected to evolve further with the advent of new
technologies including next generation sequencing.
SNPs Sample Size
(Cases, Controls)
Region Mapped gene Risk Allele
Frequency
p-Value OR or beta 95% CI (text) References
rs3814113 3,769, 4,396 9p22.2 BNC2 - RPL31P42 0.68 4E-29 (All invasive) 1.21 [1.17-1.25]
rs3814113 3,769, 4,396 9p22.2 BNC2 - RPL31P42 0.68 4E-32 (Serous
invasive)
1.28 [1.23-1.33] [96]
rs10088218 3,769, 4,396 8q24.21 MIR1208 - MIR3686 0.87 3E-12 (All invasive) 1.18 [1.13-1.24] [96]
rs10088218 3,769, 4,396 8q24.21 MIR1208 - MIR3686 0.87 1E-17 (Serous
invasive)
1.29 [1.21-1.36] [96]
rs2072590 3,769, 4,396 2q31.1 HOXD-AS1 0.32 5E-11 (All invasive) 1.11 [1.08-1.15] [96]
rs2072590 3,769, 4,396 2q31.1 HOXD-AS1 0.32 3E-10 (Serous
invasive)
1.13 [1.09-1.18] [96]
rs7651446 3,769, 4,396 3q25.31 TIPARP 0.05 2E-29 (All invasive) 1.44 [1.35-1.54] [96]
rs7651446 3,769, 4,396 3q25.31 TIPARP 0.05 2E-34 (Serous
invasive)
1.59 [1.48-1.71] [96]
rs8170 3,769, 4,396 19p13.11 BABAM1 0.19 2E-7 (All invasive) 1.11 [1.07-1.15] [96]
rs8170 3,769, 4,396 19p13.11 BABAM1 0.19 3E-14 (Serous
invasive)
1.19 [1.14-1.25] [96]
rs9303542 3,769, 4,396 17q21.32 SKAP1 0.27 6E-9 (All invasive) 1.12 [1.08-1.16] [96]
rs9303542 3,769, 4,396 17q21.32 SKAP1 0.27 3E-10 (Serous
invasive)
1.14 [1.09-1.18] [96]
rs11782652 3,769, 4,396 8q21.13 CHMP4C 0.07 6E-9 (All invasive) 1.19 [1.12-1.26] [96]
rs11782652 3,769, 4,396 8q21.13 CHMP4C 0.07 7E-10 (Serous
invasive)
1.24 [1.16-1.33] [96]
rs1243180 3,769, 4,396 10p12.31 MLLT10 0.31 2E-8 (All invasive) 1.10 [1.06-1.13] [96]
rs1243180 3,769, 4,396 10p12.31 MLLT10 0.31 1E-7 (Serous invasive) 1.11 [1.07-1.15] [96]
rs757210 3,769, 4,396 17q12 HNF1B 0.37 8E-10 (Serous
invasive)
1.12 [1.08-1.17] [96]
rs8170 1,768, 2,353 19p13.11 BABAM1 NR 4E-6 (Susceptibility) 1.12 [1.07-1.17]
rs2363956 1,768, 2,353 19p13.11 ANKLE1 NR 1E-7 (Susceptibility) 1.10 [1.06-1.15]
rs2072590 1,768, 2,354 2q31.1 HOXD-AS1 NR 5E-14 1.16 [1.12-1.21]
rs2665390 1,768, 2,354 3q25.31 TIPARP NR 3E-7 1.19 [1.11-1.27] [97]
rs10088218 1,768, 2,354 8q24.21 MIR1208 - MIR3686 NR 3E-9 1.19 [1.12-1.25] [97]
rs9303542 1,768 , 2,354 17q21.32 SKAP1 NR 1E-6 1.11 [1.06-1.16] [97]
rs7521902 1,768, 2,354 1p36.12 WNT4 - MIR4418 NR 5E-6 1.12 [1.07-1.18] [97]
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rs12794435 1,768, 2,354 11p14.3 LUZP2 - RPL36AP40 NR 5E-6 1.16 [1.09-1.23] [97]
rs2084881 1,768, 2,354 17q21.32 SKAP1 NR 2E-6 1.12 [1.07-1.18] [97]
rs3814113 1,817, 2,353 9p22.2 BNC2 - RPL31P42 0.68 5E-19 1.22 [1.16-1.27]
Table 1: GWAS of ovarian cancer*
*Table modified from NHGRI catalogue.
Epigenetic Therapies in Ovarian Cancer
Epigenetic regulation involves the effects mediated by reversible,
inheritable influences in the transcriptome that are independent of any
changes in the DNA sequence. In the normal homeostatic state, such
regulation is responsible towards achieving a definite control over cell
fate and determination [34]; various altered epigenetic mechanisms
are associated with transformation. The most studied epigenetic
modifications include DNA Methylation (DNMT), Histone
Modifications (HDAC), miRNA regulation and nucleosome
positioning. In the context of tumor progression global DNA
hypomethylation of tumor cells compared to normal cells was the first
example of association of epigenetic modifications [35]. Continuing
research identified that hypermethylation of tumor suppressor genes
that leads to their silencing and oncogene activation through
hypomethylation play a significant role in tumor development [36,37].
Aberrant patterns of DNA methylation is a widespread phenomenon
in progression of ovarian cancer with hypermethylation of BRCA1,
RASSF1A, APC, p14ARF, p16INK4A, DAPKand MLH1 being most
well studied [38,39]. The aberrant epigenetic signatures provided by
these genes serve as predictive as well as prognostic biomarkers for
evaluating the efficacy of epigenetic drugs.
The development of epigenetic therapies for cancer has targeted
three critical components of epigenetic regulation viz. DNA
methylation, histone modifications and post translational gene
regulation by miRNAs. In ovarian cancer, epigenetic drugs have been
effective in enhancing drug sensitivity of ovarian cancer cell lines and
also in vivo experimentation mostly through re-sensitization of
chemoresistant tumor cells to the action of conventional therapy
[40].A number of DNMT inhibitors (DNMTi, Table 2) and HDAC
inhibitors (HDACi, Table 3) are currently progressing through clinical
trials. Concurrently, miRNA targeting compounds, Histone Methyl
Transferase and Histone Demethylase Inhibitors (HMTi and HDMi
respectively) are currently being studied for possible preclinical
efficacy.
DNMT inhibitors Status of Clinical trial
SGI-110 Preclinical evaluation in progress
RG108 Preclinical evaluation in progress
SGI-1027 Preclinical evaluation in progress
MG98 Preclinical evaluation in progress
5-fluoro-2-deoxycytidine Phase I
5-Azacytidine (Vidaza) Completed; US FDA approved
Decitabine (Dacogen) Completed; US FDA approved
Table 2: DNA demethylating agents in clinical development
HDAC inhibitors Status of Clinical trial
JNJ26481585 Preclinical
Dacinostat Preclinical
Belinostat (PXD101) Phase II
Resminostat (4SC-201) Phase II
Panobinostat Phase III
Etinostat Phase II
Vornistat(SAHA); Zolina Completed; US FDA approved (2007)
Romidepsin Completed; US FDA 2009
Table 3: Histone deacetylase inhibitors in clinical development
DNA demethylating agents in ovarian cancer
Despite the reported association of aberrant methylation in ovarian
cancer, clinical experience of DNMTi is limited. The first compounds
inhibiting DNA methylation approved by the FDA for the treatment
of the disease were 5-Azacytidine (5-aza-C, Vidaza) and its
deoxyribose analog, 5-Aza-2′-Deoxycytidine (5-aza-dC, Decitabine)
[41,42]. Their effects have been attributed to activation of suppressed
genes and thereby were directly related to reversal of epigenetic
alterations [43,44]. DNMTi are believed to resensitize the
chemoresistant tumors towards drugs [40]. In one study, treatment
with decitabine re-expressed the DNA repair gene hMLH1 in
platinum resistant A2780/CP70 ovarian cancer cells, and xenograft
tumors derived from these cells were sensitized by decitabine to
cisplatin, carboplatin, temozolomide, and epirubicin [45]. Phase II
trials in ovarian cancer patients with methylated hMLH1 DNA in
plasma was initiated with carboplatin alone or with decitabine to
determine the role of the latter as a platinum sensitizer. However, this
trial was prematurely terminated due to higher toxicity as compared
with carboplatin monotherapy. Another phase II trial of thirty patients
with platinum-resistant or -refractory ovarian cancer was conducted
using a combination regimen involving azacitidine [46]. Most
prominent side effects were myelosupression, fatigue and nausea.
Thereby, most early trials for epigenetic drugs were limited by toxicity,
more particularly by myelosupression [47]. More recently however,
optimized lower doses of DNMTi like decitabine or 5-Aza-dC are
suggested to be more effective in inducing DNA demethylation in a
preclinical setup [48]. This has inspired the redesign of clinical trials
with new regimens using DNMTIs either as single agents or in
combination with other chemotherapeutic drugs [49], which could
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pave the way for the future applications of these drugs in treatment of
ovarian cancer.
Histone deacetylase inhibitors in ovarian cancer
Acetylation and deacetylation of histones are well established
permissive and repressive marks for gene expression
respectively.These processes are mediated by specific enzymes
described as Histone Acetyltransferases (HATs) and Histone
Deacetylase (HDAC) respectively. HDACs and HATs regulate gene
expression through chromatin remodeling during several normal
developmental processes [50]. Certain alterations in the established
dynamic equilibrium of the normal state can lead transformation.This
provides the rationale for the use of HAT and HDAC inhibitors as
cancer drugs [51]. Pan-HDAC inhibitors trichostatin A and butyric
acid were reported to be effective in preclinical studies [52], but
demonstrated limited clinical activity [53]. The first demonstrated
clinically effective HDACi was Depsipeptide [54,55] that remains to be
tested in ovarian cancer. Vorinostat (SAHA) is another HDACi and is
a small molecule that binds directly in the active site of the enzyme in
the presence of zinc. Oral route of administration and good
bioavailability of Vorinostat is reported following treatment of
cutaneous T-cell lymphoma [56]; it has progressed to phase II trials in
non-selected, pretreated recurrent ovarian cancer patients, relapsing
within 12 months after platinum based therapy [57]. Belinostatt
(PDX101) is currently in Phase II clinical trials in combination with
cisplatin and carboplatin and exhibits increased tolerability and 31%
objective response rate in patients [58]. Full exploration of the
biological potential of these drugs can be realized only after there is a
greater understanding of their molecular mechanism of action.
New Cytotoxic Reagents
While research into the underlying molecular mechanisms of
ovarian cancer metastasis is still in progress, progressive resistance to
treatment remains the main challenge to cure this cancer. To treat
patients with chemo-resistant recurrent ovarian cancer, novel
cytotoxic agents have been generated and trialled [59]. These reagents
include a marine-derived alkaloid trabectedin, a microtubule
stabilizing agent patupilone and a glutathione analog, canfosfamide.
Combined data analysis from 3 phase-II clinical trials on ovarian
cancer patients with recurrence after carboplatin and/or paclitaxel
treatment demonstrated that trabectedin is an efficacious single agent
compared to the standard chemo-treatments especially for platinum
sensitive patients [60]. A randomised phase II trial showed an
improved progression free survival and an increased response rate on
late relapsed patients using combined trabectedin and Pegylated
Liposomal Doxorubicin (PLD) compared to PLD alone [61]. More
specifically, a combined trabectedin and PLD regimen demonstrated
an enhanced response in platinum sensitive patients [62], suggesting
that it is a new chemo-treatment option for ovarian cancer in late
relapse. However, patupilone failed to improve the outcome of
relapsed patients [63]. A phase III study on canfosfamide showed a
promising improvement of overall survival time over PLD suggesting
its potential as a third line treatment for platinum-refractory or -
resistant ovarian cancer [64].
Molecular Signalling Pathway Targeted Therapies
Inhibition of activated signalling pathways, DNA repair enzymes
and proteases has been vigorously investigated to treat ovarian cancer
with representative strategies as summarised in Figure 2. ErbB2 or
Her2/neu is a member of the ErbB family of Receptor Tyrosine
Kinases (RTKs) and a well-known target for efficacious treatment of
breast cancer. Treatment with the Her2/neu neutralising antibody,
Herceptin, has improved the outcome of women with Her2 positive
breast cancer [65], but not significantly in ovarian cancer [3]. On the
other hand, ErbB1 or EGFR, is over-expressed in 30-70% of ovarian
cancer patients and associated with poor outcome [66]. A phase II trial
showed that combined application of the EGFR inhibitor, cetuximab,
with carboplatin and paclitaxel gave no prolonged progression free
survival time compared to the conventional treatment [67]. However,
the most exciting outcome is that two phase III trials using an
inhibitor of the VEGFR and PDGF induced angiogenesis signalling
pathway, Bevacizumab (Avastin), significantly prolonged disease free
survival time in particular for women with advanced stage disease
[68]. The folate transporter, αFR, is over-expressed in more than 90%
of non-mucinous ovarian cancer and correlates with high tumor grade
[69]. An extended phase II trial with relapsed platinum-sensitive
ovarian cancer patients, using a monoclonal antibody farletuzumab to
inhibit this pathway, showed a trend toward prolonged PFS [70].
Other potential molecular targets in ovarian cancer treatment involve
Poly ADP-Ribose Polymerase (PARP), Src family members,
Ras/Raf/MEK/MAPK pathway, JAK/STAT pathway and the
PI3K/AKT/mTOR pathway [3,71,72]. For example, clinical trials with
olaparib to inhibit PARP, Zibotentan to inhibit endothelinA, and a Src
kinase inhibitor AZD0530 are still in progress [71]. Preclinical studies
have shown their roles in reduced proliferation, migration, invasion,
adhesion and chemoresistance using established cells lines in
preclinical in vitro and in vivo animal xenograft models. Early research
showed expression of Metalloproteases (MMPs) and their correlation
with poor prognosis in ovarian cancer patients as reviewed [73].
Interestingly, expression of MMP2 in the tumor stroma is associated
with a poor outcome in women with ovarian cancer [74,75]. However,
clinical trials on MMP inhibitors alone or in combination with
chemotherapy showed limited cytotoxity in women with this cancer
[76]. It has been acknowledged that the current inhibitors of MMPs
have a broad spectrum and that specificity remains to be improved. In
addition, new strategies have been proposed to design next generation
approaches, such as using highly selective inhibitors or blocking
antibodies against individual membrane-bound MMPs [73]. It has
been long established that protein levels of Urokinase Plasminogen
Activator (uPA), its receptors (uPAR) and endogenous inhibitors
(PAI-1 and PAI-2) are associated with short progression free and
overall survival time for ovarian cancer patients implying their
therapeutic target potential [77,78]. Different strategies to inhibit uPA
activity are under investigation [79] and an elegant delivery system
using uPA-targeted nanobins has shown promise in reducing ovarian
tumor burden in an in vivo mouse model [80]. Recent studies have
also revealed aberrant expression of members of a serine protease
family, Kallikreins (KLKs), in this cancer as reviewed [81], with
simultaneous expression of several KLKs reported [78]. Activation
between MMPs, uPA and KLKs via hydrolysis of their respective pro-
forms has been reported implying a proteolytic network involving
these protease families of enzymes [82,83]. Importantly, we are
learning more of the roles of the KLK enzymes, using endogenous
inhibitors and those recently designed by scientists and
pharmaceutical experts. For example, Sunflower Trypsin Inhibitors
(SFTIs) selectively blocked the activity of KLK4 [84] and KLK7 [85] in
cancer cell based assays. We have reported that adding selective KLK4
SFTI-FCQR reduced multicellular aggregation in ovarian cancer
SKOV3 cells and increased sensitivity to Taxol in a 3D-suspension
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culture platform [86]. Currently these inhibitors are in preclinical
studies using in vitro and in vivo animal models [87] which hopefully
can be extrapolated to a clinical setting. Overall, numerous potential
molecular therapeutic targets have been identified although we still
face the challenge to test their potential in preclinical and clinical
studies and identify which individual patients will benefit from a given
drug.
Figure 2: Schematic showing current drugs in preclinical or clinical
trials for the treatment of ovarian cancer and the cell signaling
proteins, kinases, receptors and protease pathways that they inhibit.
Integrated Platforms to Identify Therapeutic Targets
for Individual Patients
Over the past 2 decades following completion of the human genome
project and advancing technologies in transcriptome analysis, cancer
patient datasets, with and without treatment, have been generated,
such as in the The Cancer Genome Atlas (TCGA, http://
cancergenome.nih.gov/) and Oncomine (https://www.oncomine.org)
[88]. For example, transcriptome analysis has revealed chemo-
response associated genes in ovarian cancer patient tissue samples,
such as for platinum and taxane drugs [89,90]. In addition, proteomics
platforms based on Mass Spectrometry (MS) and antibody based
approaches, such as antibody microarray, have already provided
critical tools to identify new targets for personalized treatment for
cancer patients [91]. Moreover, platinum resistance associated targets
have been discovered using the MS-based proteomics approach
integrated with transcriptome analysis in ovarian cancer cells [92].
Furthermore, phosphoprotein and phosphopeptide enrichment
strategies combined with quantitative MS have been used to discover
active kinases [93]. A phase II clinical trial was carried out to evaluate
the clinical benefit of vandetanib, a multi-kinase inhibitor of VEGFR,
EGFR and RET, but the data showed that the daily monotherapy had
no clinical benefit in women with recurrent ovarian cancer [94]. In
this study, an antibody based reverse-phase protein lysate array was
applied on paired tissue biopsies which detected both phosphorylated-
(p)EGFR and pVEGF receptor-2, but only pEGRF was inhibited. The
outcome of this study revealed that the remaining challenge for a
successful treatment is that the identified biomarkers need to be
validated in an ex vivo assay to determine the cellular response to the
inhibitors using tissues/cells from patients. In this regard, numerous 3-
Dimensional (3D) cell culture platforms to better replicate the tumor
microenvironment akin to that seen in patients have been generated
[6,95-98]. Overall, integrated strategies like these are needed to help
choose the most efficacious treatment agents for individual patients.
Future Direction in Ovarian Cancer Research and
Treatment
In addition to the initial crucial cyto-reductive surgery, we still need
efficacious therapeutic approaches to treat the remaining ovarian
cancer cells and prevent tumor recurrence and metastases.
Pharmacogenomic profiling will identify the molecular signalling
network(s) of which inhibition will limit tumor growth, and also
predict how to choose candidate agents. However, determination of
which identified pathways to target as the therapeutic approach for
individual patients remains a challenge to clinical oncologists.
Application of tumor derived cells from patients in ex vivo assays may
provide the key to predict the response for individual patients and a
clearer direction to a more efficacious therapeutic approach.
Alternatively, in vivo animal models with patient derived ex vivo
tumor material may also be the tool to help identify the most
efficacious therapeutic agents. In this way, the distance between our
current understanding of the underlying biology of ovarian cancer
progression and treatment resistance, and application of our
knowledge in clinical management will be shortened. Importantly, we
will be on the way to reach our ultimate goal that is to prolong the
survival time and improve the quality of life of women with ovarian
cancer.
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